drugset / Trial / NCT01172847

A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers

NCT01172847

Phase 1 Completed 24 enrolled Hoffmann-La Roche
RandomizedCrossoverOpen-label

Summary

This open label, randomized, three-period crossover study will evaluate the effect of co-administration of Tamiflu (oseltamivir) and rimantadine on the pharmacokinetics of Tamiflu and rimantadine. Healthy volunteers will receive multiple oral doses of Tamiflu, rimantadine or Tamiflu plus rimantadine in random order, with a minimum wash-out period of 7 days between treatments. Anticipated time on study is up to 11 weeks.

Timeline

Start
2009-08
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 75 mg Oral
Subject rimantadine Small molecule 100 mg Oral

Indications

No indication recorded.